Last reviewed · How we verify
What is a PDUFA date?
How PDUFA dates are set
When a sponsor files an NDA (New Drug Application) or BLA (Biologics License Application), the FDA assigns a PDUFA date — usually 10 months from filing for standard review, 6 months for priority review. The deadline is set under the Prescription Drug User Fee Act, which Congress reauthorises every 5 years. The most recent reauthorisation (PDUFA VII, FY2023-2027) added more time for complex review programmes like cell + gene therapy.
Standard vs priority review
Priority review is granted when a drug offers a significant improvement over existing treatments for a serious condition. Sponsors qualify via Breakthrough Therapy designation, Fast Track, Accelerated Approval, or specific disease-area criteria (e.g. paediatric extensions). Priority review shortens the PDUFA clock by 4 months — material time savings worth tens of millions in NPV terms.
What happens when a PDUFA date arrives
On (or close to) the PDUFA date, the FDA issues one of: (1) Approval — sponsor commercialises; (2) Complete Response Letter (CRL) — issues to resolve before re-submission; (3) Tentative approval — generic/biosimilar where exclusivity blocks marketing; (4) Major Amendment Extension — sponsor submits substantial new data, FDA extends by up to 3 months. The FDA does NOT have to wait for the PDUFA date — many decisions land days or weeks early.
Why PDUFA dates shift
Three reasons: (a) Major Amendment Extension (most common — sponsor adds data, extends 3 months); (b) Information Request — FDA asks for clarification, clock pauses; (c) Manufacturing inspection delays (rare but material — Bharat Biotech, Lupin etc. have seen delays). Sponsors disclose any extension via 8-K within 4 business days.
What does an FDA Advisory Committee mean?
For contested filings (novel mechanism, narrow benefit, safety signal), the FDA may convene an AdCom — a panel of independent experts who vote on whether to approve. The FDA is not bound by the vote but follows it in ~80% of cases. AdComs typically happen 2–4 months before the PDUFA date. Outcome data is public (FDA briefing documents, voting transcripts, written sponsor responses).
FAQ
Is the PDUFA date public?
Yes. The FDA discloses the PDUFA date when it accepts the application for filing. The sponsor typically announces it in an 8-K + press release.
How often does the FDA miss the PDUFA date?
For NDAs/BLAs at the PDUFA action date itself — extremely rarely. The 3-month Major Amendment Extension is the more common adjustment, used in ~15% of filings.
Can the FDA approve before the PDUFA date?
Yes — and it often does. Approvals 1-3 weeks before the official date are common, especially for breakthrough-therapy products.
What's the difference between PDUFA and BsUFA?
BsUFA (Biosimilar User Fee Act) is the parallel programme for biosimilars. PDUFA covers new drugs + biologics; BsUFA covers biosimilars. Different fee structures, same overall mechanism.